???The acceptance of CRi solutions by the world???s leading pharmaceutical companies further establishes the trend for drug development efforts, particularly in areas such as oncology, to focus on developing targeted therapies for more molecularly defined patient populations,??? said George Abe, chief executive officer at CRi. ???Researchers realize the significant capabilities of CRi???s platform